Compare McKesson Corporation (MCK) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Skyworks Solutions Inc — how do they compare? McKesson Corporation trades at $828.48 (market cap $97.35B), while Skyworks Solutions Inc trades at $62.61 (market cap $8.99B). The key difference: McKesson Corporation is far larger — about 10.8× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| MCK | SWKS | |
|---|---|---|
Market Cap | $97.35B | $8.99B |
Sector | Health | Technology |
52-Week High | $995.69 | $83.40 |
52-Week Low | $659.01 | $52.50 |
Enterprise Value | $101.98B | $8.76B |
Dividend Yield | 0.39% | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Skyworks Solutions (SWKS) trades at $59.83, up 0.88% on the day, with a bearish technical signal but strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue has declined from $5.5B in 2022 to $4.1B in 2025, though profitability metrics like a 41.08% gross margin remain solid. Recent news highlights product launches in AI and EV sectors and an ongoing legal investigation.
The outlook is mixed: analyst consensus is bullish with a $75.88 price target (58.34% buy ratings), but technicals and declining revenue pose risks. Key opportunities include diversification beyond mobile chips and AI-driven demand, while risks involve customer concentration, margin pressure, and legal scrutiny. The stock offers a dividend yield above 4%, supported by cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
